title: Overview: A New Era of Cancer Genomics in Lymphoid Malignancies.
abstract: Novel technologies including next-generation sequencing have not only delineated the molecular pathogenesis of lymphoid malignancies but also identified novel biomarkers predicting the outcome of specific therapies. In addition, many actionable genetic alterations, which can be targeted by either specific therapeutic compounds or monoclonal antibodies, have been discovered. An appropriate selection of the patients enrolled in clinical trials using novel drugs targeting specific mutations will usher in a new era of personalized medicine in clinical practice of lymphoid malignancies.
authors.affiliation: Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Iida
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood; D002986:Clinical Trials as Topic; D015894:Genome, Human; D023281:Genomics / Q000639:trends*; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000235:genetics*; D008223:Lymphoma / Q000188:drug therapy* / Q000235:genetics*; D058990:Molecular Targeted Therapy / Q000639:trends*; D009154:Mutation; D010880:Piperidines; D057285:Precision Medicine / Q000639:trends*; D011720:Pyrazoles / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D007211:Indoles; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; D013449:Sulfonamides; C551803:ibrutinib; D000077484:Vemurafenib; D000225:Adenine